Tidal Investments LLC Sells 6,827 Shares of Glaukos Co. (NYSE:GKOS)

Tidal Investments LLC lowered its position in Glaukos Co. (NYSE:GKOS - Free Report) by 45.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,081 shares of the medical instruments supplier's stock after selling 6,827 shares during the quarter. Tidal Investments LLC's holdings in Glaukos were worth $1,212,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. State of Wyoming grew its stake in Glaukos by 2.3% in the fourth quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier's stock valued at $487,000 after purchasing an additional 72 shares in the last quarter. Quadrant Capital Group LLC grew its stake in Glaukos by 3.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock valued at $345,000 after purchasing an additional 73 shares in the last quarter. Mutual of America Capital Management LLC grew its stake in Glaukos by 1.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock valued at $1,252,000 after purchasing an additional 89 shares in the last quarter. HighTower Advisors LLC grew its stake in Glaukos by 2.8% in the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock valued at $495,000 after purchasing an additional 91 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in shares of Glaukos by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock worth $4,003,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at $5,708,568.04. The trade was a 2.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.40% of the company's stock.

Wall Street Analysts Forecast Growth

GKOS has been the subject of a number of analyst reports. Wells Fargo & Company cut Glaukos from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $160.00 to $86.00 in a research report on Thursday, May 1st. Truist Financial restated a "buy" rating and set a $135.00 price target (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Needham & Company LLC reduced their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Mizuho reduced their price target on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 16th. Finally, Stephens reduced their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, Glaukos presently has a consensus rating of "Moderate Buy" and a consensus target price of $134.67.

Glaukos Stock Performance

NYSE GKOS traded down $1.85 during trading on Wednesday, reaching $95.12. 591,518 shares of the company's stock were exchanged, compared to its average volume of 699,240. The business has a 50 day moving average price of $93.25 and a 200-day moving average price of $124.03. The stock has a market capitalization of $5.44 billion, a P/E ratio of -33.14 and a beta of 0.83. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a fifty-two week low of $77.10 and a fifty-two week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company had revenue of $106.66 million during the quarter, compared to analysts' expectations of $102.78 million. During the same quarter in the previous year, the company posted ($0.70) earnings per share. The business's revenue was up 24.6% on a year-over-year basis. Sell-side analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.